abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile - Kereiakes, Dean J.; Lincoff, A.Michael; Anderson, Keaven M.; Achenbach, Robert; Patel, Kamlesh; Barnathan, Elliot; Califf, Robert M.; Topol, Eric J.; EPIC Investigators; EPILOG investigators; EPISTENT investigators (American Journal of Cardiology, 2002)